Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study

@article{Huober2010EffectON,
  title={Effect of neoadjuvant anthracycline–taxane-based chemotherapy in different biological breast cancer phenotypes: overall results from the GeparTrio study},
  author={Jens B. Huober and Gunter von Minckwitz and Carsten Denkert and Hans Tesch and Erich Weiss and Dirk Michael Zahm and Antje Kristina Belau and Fariba Khandan and Maik Hauschild and Christoph Thomssen and Bernhard Hoegel and Silvia Darb-Esfahani and Keyur Mehta and Sibylle Loibl},
  journal={Breast Cancer Research and Treatment},
  year={2010},
  volume={124},
  pages={133-140}
}
In order to explore the effect of neoadjuvant chemotherapy (NACT) on clinical mid-course and pathological complete response (pCR) at surgery in different biological breast cancer subtypes. The GeparTrio study included 2,072 patients with operable or locally advanced breast cancer. After two cycles with docetaxel, doxorubicin and cyclophosphamide (TAC) patients were randomized according to their clinical response. Clinical and biological factors were assessed for predicting clinically mid-course… CONTINUE READING